GERON CORP Restructuring Charges
GERON CORP (GERN) reported Restructuring Charges of -$157.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-05
- GERON CORP restructuring charges for the quarter ending 2026-06-30 was -$157.00K.
- GERON CORP restructuring charges for the quarter ending 2026-03-31 was -$394.00K.
- GERON CORP restructuring charges for the quarter ending 2025-06-30 was $0.00.
- GERON CORP restructuring charges for the quarter ending 2025-03-31 was $0.00.
- GERON CORP restructuring charges for fiscal 2025 was $17.03M.
- GERON CORP restructuring charges for fiscal 2024 was $0.00.
- GERON CORP restructuring charges for fiscal 2023 was $0.00.
- GERON CORP restructuring charges for fiscal 2015 was $1.31M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$157.00K 10-Q · filed 2026-08-05 | -$551.00K 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$394.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $17.03M 10-K · filed 2026-03-02 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$41.00K derived: sum of 2 quarters · filed 2018-03-16 | $900.00K derived: sum of 3 quarters · filed 2018-03-16 | $1.31M 10-K · filed 2018-03-16 |
| 2015-09-30 | -$41.00K 10-Q · filed 2016-11-03 | $900.00K derived: sum of 2 quarters · filed 2016-11-03 | $1.31M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $941.00K 10-Q · filed 2016-08-03 | $1.35M 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | $406.00K 10-Q · filed 2016-05-05 | |||
| 2013-12-31 | $430.00K 10-K · filed 2015-03-11 | $546.00K derived: sum of 2 quarters · filed 2015-03-11 | $1.38M derived: sum of 3 quarters · filed 2015-03-11 | $1.46M 10-K · filed 2016-03-10 |
| 2013-09-30 | $116.00K 10-Q · filed 2014-11-05 | $954.00K derived: sum of 2 quarters · filed 2014-11-05 | $1.03M 10-Q · filed 2014-11-05 | $3.73M derived: sum of 4 quarters · filed 2014-11-05 |
| 2013-06-30 | $838.00K 10-Q · filed 2014-08-11 | $916.00K 10-Q · filed 2014-08-11 | $3.62M derived: sum of 3 quarters · filed 2014-08-11 | |
| 2013-03-31 | $78.00K 10-Q · filed 2013-05-03 | $2.78M derived: sum of 2 quarters · filed 2014-03-17 | ||
| 2012-12-31 | $2.70M 10-K · filed 2014-03-17 | $2.70M 10-K · filed 2015-03-11 | ||
| 2011-12-31 | $5.45M 10-K · filed 2013-03-15 | $5.45M 10-K · filed 2014-03-17 | ||
| 2010-12-31 | $0.00 10-K · filed 2012-03-07 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |